Beam Therapeutics Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Beam Therapeutics stock.
View analyst ratings for Beam Therapeutics or view top-rated stocks.

7 brokerages have issued 1 year price targets for Beam Therapeutics' stock. Their BEAM stock forecasts range from $41.00 to $152.00. On average, they expect Beam Therapeutics' share price to reach $110.86 in the next twelve months. This suggests a possible upside of 174.3% from the stock's current price.
View analysts' price targets for Beam Therapeutics or view top-rated stocks among Wall Street analysts.

Beam Therapeutics' stock was trading at $79.69 at the beginning of the year. Since then, BEAM stock has decreased by 49.3% and is now trading at $40.42.
View the best growth stocks for 2022 here.

Beam Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Beam Therapeutics.

Beam Therapeutics Inc. (NASDAQ:BEAM) announced its quarterly earnings results on Monday, May, 9th. The company reported ($1.01) EPS for the quarter, beating analysts' consensus estimates of ($1.10) by $0.09. The company earned $8.40 million during the quarter, compared to analyst estimates of $44.15 million. Beam Therapeutics had a negative net margin of 395.37% and a negative trailing twelve-month return on equity of 28.02%. The company's revenue was up 139900.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($3.35) EPS.
View Beam Therapeutics' earnings history.

1 employees have rated Beam Therapeutics CEO on Glassdoor.com. has an approval rating of 100% among Beam Therapeutics' employees. This puts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Beam Therapeutics include Qiagen (QGEN), Qiagen (QGEN), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exelixis (EXEL), Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), Ginkgo Bioworks (DNA), Novavax (NVAX), Ablynx (ABLYF), Denali Therapeutics (DNLI), Vir Biotechnology (VIR), Abcam (ABCM), Fate Therapeutics (FATE) and Bavarian Nordic A/S (BVNRY).
View all of BEAM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Square (SQ), Skyworks Solutions (SWKS), Akoustis Technologies (AKTS), Invitae (NVTA), QUALCOMM (QCOM) and Alector (ALEC).

(BEAM) raised $101 million in an initial public offering (IPO) on Thursday, February 6th 2020. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Beam Therapeutics trades on the NASDAQ under the ticker symbol "BEAM."

Shares of BEAM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BEAM stock can currently be purchased for approximately $40.42.

Beam Therapeutics (NASDAQ:BEAM) has a market capitalization of $2.84 billion and generates $51.84 million in revenue each year. The company earns $-370.64 million in net income (profit) each year or ($3.610010) on an earnings per share basis.

Beam Therapeutics employs 341 workers across the globe.

Beam Therapeutics' mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The official website for Beam Therapeutics is www.beamtx.com. The company can be reached via phone at 857-327-8775 or via email at [email protected].